Figure INF-13:  Estimated HIV, HCV and HBV prevalence among injecting drug users – studies with national and sub-national coverage. Summary of all available data across EU Member States, candidate countries and Norway, 2000 to 2004

Figure INF-13

Notes:

HCV:

Countries with data available for HCV: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Estonia, Spain, Finland, Greece, Hungary, Ireland, Italy, Lithuania, Latvia, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, Turkey and United Kingdom.

Number of samples: 287

Total sample size: 408125

HIV:

Countries with data available for HIV: Austria, Belgium, Bulgaria, Czech Republic, Germany, Estonia, Denmark, Spain, Finland, France, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, Turkey and United Kingdom.

Number of samples: 433

Total sample size: 559592

HBV antibodies:

Countries with data available for HBV antibodies: Austria, Belgium, Bulgaria, Cyprus, Germany, Estonia, Spain, Ireland, Italy, Lithuania, Latvia, The Netherlands, Norway, Poland, Portugal, Slovenia, Slovakia and United Kingdom.

Number of samples: 200

Total sample size: 294277

HBV HBsAg:

Countries with data available for HBsAg: Belgium, Greece, Hungary, Ireland, Malta, The Netherlands, Poland, Portugal, Romania and Slovenia.

Number of samples: 106

Total sample size: 61805

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national focal points. See Table INF-8, Table INF-11, Table INF-14 and Table INF-15 for the original data.